Compare PACK & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACK | MNPR |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.2M | 403.4M |
| IPO Year | 2017 | 2019 |
| Metric | PACK | MNPR |
|---|---|---|
| Price | $3.45 | $61.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $6.50 | ★ $101.42 |
| AVG Volume (30 Days) | ★ 634.3K | 145.1K |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $395,000,000.00 | N/A |
| Revenue This Year | $11.99 | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $2.91 | $26.06 |
| 52 Week High | $6.31 | $105.00 |
| Indicator | PACK | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 28.66 | 58.07 |
| Support Level | $3.34 | $50.92 |
| Resistance Level | $3.79 | $89.51 |
| Average True Range (ATR) | 0.32 | 3.09 |
| MACD | -0.16 | 1.10 |
| Stochastic Oscillator | 12.21 | 91.62 |
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. Geographically, it derives a majority of its revenue from Europe/Asia. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.